Latest Conference Articles

Late-breaking data presented by Dr. Christopher Warren indicates travelers with food allergy lack confidence in regulations and accommodations put in place for air travel.

Altman spoke in a recent interview about the main takeaways from his AAAAI presentation, during which he discussed systems biology research into allergic diseases.

"You want to be empowering children to be proactive and managing their medical condition in the healthiest, safest possible way," Dr. Christopher Warren said in an interview at AAAAI 2023.

In an interview segment with Nelson, she described elements from her AAAAI presentation, including when to use biologics or JAK inhibitors and what goes into patch testing for allergic skin reactions.

Dr. Christopher Warren discusses the study he presented at AAAAI 2023 Annual Meeting that found 98% of participants experienced added anxiety when traveling due to their food allergy, with a "lamentingly high number" of negative experiences.

This interview with Nelson featured a discussion of topics covered in her presentation for AAAAI, including differentiating allergic and non-allergic skin conditions.

In this interview segment on his AAAAI presentation, Dellon described some of the study’s limitations and more about the condition of eosinophilic esophagitis.

According to data from the AAAAI 2023 Annual Meeting, individuals with food allergies face numerous barriers when managing their condition while flying, with only 15% receiving epinephrine.

In an interview regarding his AAAAI poster session, Dellon described a sub-analysis of new phase 3 trial data on dupilumab for eosinophilic esophagitis patients.

Dr. David Dworaczyk explains phase 3 data showing a single intranasal dose of epinephrine produced a higher and more prolonged plasma curve compared to an intramuscular 0.3 mg autoinjector.

In his HCPLive interview at the 2023 AAAAI conference, Gallo elaborated on his team’s research into the skin microbiome’s connection to atopic dermatitis and future research.

In phase 3 data presented at the AAAAI conference, an investigational intranasal epinephrine spray was found to have higher and more sustained pharmacokinetics than the standard reference product.

In an interview with HCPLive, Gallo described his AAAAI presentation on the function of the skin microbiome, as well as the microbiome’s connection to atopic dermatitis.

New data from the 2023 AAAAI conference showed that the mice with atopic dermatitis used in the study had different responses to ILC2 activity depending on their age.

Bryn Pharma CEO shares promising data on a novel intranasal epinephrine spray called Utuly during the AAAAI 2023 Annual Meeting.

In another segment of his interview at the 2023 AAAAI conference, Shamji spoke about comparisons between subcutaneous and sublingual immunotherapies.

A study from the AAAAI 2023 Annual Meeting reveals racial and ethnic disparities in the management of severe asthma and highlights the need for interventions to improve care escalation for Black and Hispanic/Latino patients.

In an interview at the 2023 AAAAI conference, Shamji spoke about the key points made in his presentation titled ‘Biomarkers for the Response to Allergen Immunotherapy.’

Chovatiya discussed his Winter Clinical Miami presentation, common concerns over black box warnings for JAK inhibitors, and unmet needs of alopecia areata patients.

In his latest HCPLive interview, regarding a presentation at Winter Clinical Miami, Chovatiya spoke about recent JAK inhibitor developments, alopecia areata, baricitinib, and more.

In her latest HCPLive interview, Ablon discusses her Winter Clinical Miami dermatology conference presentation ‘Evaluating the Aesthetic Patient’ and its biggest takeaways.

In another segment of her interview with HCPLive, Graber explored some of the latest treatment developments for acne and rosacea covered in her 2023 Winter Clinical Miami presentation.

In an HCPLive interview on her Winter Clinical Miami presentation, Graber describes several new developments in the dermatology space regarding acne and rosacea treatments.

In another segment of his interview, Mark Lebwohl, MD, discussed the various ways to address different psoriasis patients depending on their backgrounds with obesity, cancer, and psoriatic arthritis.

In his recent interview, Mark Lebwohl, MD, spoke about his Winter Clinical Miami presentation titled ‘Psoriasis: Which Drug for Which Patient?’ and some of its highlights.

Anisha Dua, MD, MPH, emphasized the looming workforce shortage, the challenges of attracting medical students to this field, and how practices changed during the COVID-19 pandemic.

The connection between different ADHD subtypes and mood disorders has not been fully explored.

Singh presented during the recent APSARD conference. onthe topic of ADHD and bipolar disorder.